Kymera Therapeutics Inc faces a challenging day in the market as investors react to recent developments.
Kymera Therapeutics Inc (NASDAQ:KYMR) is experiencing a notable decline, with its stock sliding by 3.02% as of the latest market close. The company, which specializes in innovative therapies, is under scrutiny as it awaits critical data that could impact its future prospects.
Advertisement
Kymera Therapeutics Inc
KYMR.US
KYMR.US
Kymera Therapeutics Inc
WealthAwesomeMarket cap
$8.72B
52W high
$130.05
52W low
$55.26
1W change
-3.08%
Beta
1.98
Analyst Price Targets
Based on 23 analysts covering KYMR · as of Oct 6, 2026
Wall Street analysts forecast KYMR stock price to rise 28.6% over the next 12 months.
Consensus
Strong Buy4.65 / 5.00
Avg. Target
C$139.32
+28.6% Upside
Previously C$138.64 on Oct 5, 2026
Current Price
C$108.35
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KYMR's historical volatility
30-Day Vol
33.1%
Annualized
90-Day Vol
53.1%
Annualized
Trend (90d)
-14.2%
Annualized drift
90d Mean
C$102.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$106.53 | C$95.03 – C$119.42 |
| 60 trading days | C$104.74 | C$89.12 – C$123.11 |
| 90 trading days | C$102.99 | C$84.50 – C$125.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Kymera's stock faces downward pressure, particularly with upcoming data releases that could sway market sentiment.
3.02% Decline
Kymera's stock has dropped 3.02%, reflecting investor concerns ahead of critical trial data.
Bull case
If the Phase 2b data for KT-621 shows strong efficacy, it could significantly boost investor confidence and drive the stock higher.
Bear case
If the efficacy results are below expectations or if new safety concerns arise, the stock could lose more appeal, leading to further declines.
Advertisement
Market Reaction to Upcoming Data
Kymera's stock slide today can be attributed to investor anxiety surrounding the upcoming Phase 2b data for KT-621. The drug is positioned to compete with established therapies, but any results falling short of expectations could lead to further declines.
Analyst Sentiment
Wells Fargo recently assigned a price target of $151 for Kymera, highlighting the potential for significant gains if the drug meets efficacy benchmarks. However, concerns about possible safety issues have left investors wary, contributing to today's stock decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
